Form 8-K · Current report
Tyler Technologies 8-K, filed Sep 15, 2026
- Filed
- CIK
- 0000860731
- Accession no.
- 0000860731-26-000052
Summary
Tyler Technologies entered into a Rule 10b5-1 trading plan with a brokerage firm to repurchase up to $260.0 million of its common stock, with repurchases permitted to begin September 16, 2026 and ending October 29, 2026. The plan sits within a share repurchase program the board expanded in 2026, leaving $1.416 billion of remaining authorization as of September 15, 2026.
Key points
- Tyler's board authorized up to $1.0 billion of repurchases on February 3, 2026, superseding all previous authorizations, and an additional $1.5 billion on July 24, 2026.
- The repurchase program has no specified expiration date, and the board also authorized one or more Rule 10b5-1 plans.
- Buybacks are generally funded from existing cash balances and borrowings under Tyler's credit facility.
- The plan is intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934 and Tyler's insider trading policy.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 8.01Other Events
From the filing
Item 8.01 Other Events. On September 15, 2026, Tyler Technologies, Inc. (“Tyler”) entered into a Rule 10b5-1 trading plan (the “Plan”) with a brokerage firm to repurchase up to $260.0 million of our common stock. Share repurchases under the Plan may commence September 16, 2026, and will end October 29, 2026. Tyler’s share repurchase program was originally announced in October 2002 and was amended at various times from 2003 through 2026. On February 3, 2026, our Board of Directors authorized the repurchase of up to $1.0 billion of our common stock, which replaced and superseded all previous authorizations. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.